Sort   by:  
 Page size 
MetabolomicsTargeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have significantly improved outcomes in ovarian cancer (OC); however, therapy resistance remains a major clinical challenge. Here, we showed that glutamine metabolism was upregulated in PARPi-resistant OC cells and identified the g...

2026-04-08 | MTBLS14072 | MetaboLights
TranscriptomicsPARP inhibition
PARP inhibition and the effect on Arabidopsis thaliana high light tolerance
ORGANISM(S): Arabidopsis thaliana 
2012-05-01 | E-MTAB-896 | biostudies-arrayexpress
ProteomicsComprehensive selectivity profile of PARP inhibitors using a target-centric bead matrix
Explore selectivity of several PARP inhibitors against proteins of the PARP family.
ORGANISM(S): Homo sapiens (Human) 
2025-05-06 | PXD044329 | Pride
Niraparib Parp Talazoparib Olaparib 
GenomicsEssential role of poly(ADP-ribosyl)ation in cocaine action
Many of the long-term effects of cocaine on the brain's reward circuitry have been shown to be mediated by alterations in gene expression. Several chromatin modifications, including histone acetylation and methylation, have been implicated in this regulation, but the effect of other histone modifica...
ORGANISM(S): Mus musculus 
2014-02-20 | E-GEOD-55136 | biostudies-arrayexpress
TranscriptomicsIGR_Michels_PARP
Non-small cell lung cancer (NSCLC) is often treated with cisplatin (CDDP). Here, we report that two distinct poly(ADP-ribose) polymerase (PARP) inhibitors exhibited a hyperadditive combination effect with CDDP to kill NSCLC cells. A majority of CDDP-resistant cell lines and clones exhibited constitu...
ORGANISM(S): Homo sapiens 
2013-10-31 | E-MTAB-1353 | biostudies-arrayexpress
GenomicsPARP-inhibitors applied to BRCA1-null PDX models
Expression changes in BRCA1-deficient breast cancer PDX models treated with PARP-inhibitors.
PRJEB26804 | ENA
ProteomicsPBRM1 deficiency is synthetic lethal with PARP inhibitors in human cancers
Polybromo-1 (PBRM1), which encodes a specific subunit of the pBAF chromatin remodeling complex, is inactivated in multiple malignancies including 50% of clear cell renal cell carcinoma. At present, a therapeutic strategy that selectively targets PBRM1 defects does not exist. PBRM1 is involved in mul...
ORGANISM(S): Homo sapiens (Human) 
2022-02-21 | PXD017826 | Pride
Tmt Msms Parp inhibitors Cancer 
MetabolomicsThe Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells
Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribo...
2016-11-07 | MTBLS337 | MetaboLights
ProteomicsComprehensive selectivity profile of PARP inhibitors using kinobeads
Explore kinase off-targets of several PARP inhibitors using kinobeads
ORGANISM(S): Homo sapiens (Human) 
2025-05-06 | PXD045297 | Pride
Kinobeads Niraparib Parp Talazoparib Olaparib 
ProteomicsHotspot SF3B1 mutations determine response to PARP inhibitors
Hotspot mutations in the spliceosomal component gene SF3B1 underpin a number of cancers and have a neomorphic function leading to global disruption of canonical splicing and aberrant splicing of hundreds of transcripts. However, the functional consequences of this misplicing and resultant genetic vu...
ORGANISM(S): Homo sapiens (Human) 
2023-04-19 | PXD019046 | Pride
Human Sf3b1 Ms3 Tmt Cancer Parp inhibitors 
Sort   by:  
 Page size